Skip to main content

Articles

Page 38 of 42

  1. Mesenchymal stem cells (MSC) have generated a great amount of enthusiasm over the past decade as a novel therapeutic paradigm for a variety of diseases. Currently, MSC based clinical trials have been conducted...

    Authors: Shihua Wang, Xuebin Qu and Robert Chunhua Zhao
    Citation: Journal of Hematology & Oncology 2012 5:19
    Content type: Review Published on:

  2. Tissue factor (TF), an initiator of blood coagulation, participates in cancer progression and metastasis. We recently found that inhibition of MAPK/ERK upregulated both full length TF (flTF) and soluble isofor...

    Authors: Chaoquan Hu, Limin Huang, Caroline Gest, Xiaodong Xi, Anne Janin, Claudine Soria, Hong Li and He Lu
    Citation: Journal of Hematology & Oncology 2012 5:16
    Content type: Research Published on:

  11. Cell division cycle 20 (CDC20) homolog is an anaphase-promoting complex activator that is essential for cell division, but whether its expression in pancreatic ductal adenocarcinoma (PDAC) is significant is un...

    Authors: David Z Chang, Ying Ma, Baoan Ji, Yan Liu, Patrick Hwu, James L Abbruzzese, Craig Logsdon and Huamin Wang
    Citation: Journal of Hematology & Oncology 2012 5:15
    Content type: Research Published on:

  12. Peripheral blood stem cell (PBSC) mobilization, which uses plerixafor (AMD 3100), a newly developed specific inhibitor of the CXCR4 receptor, in combination with granulocyte-colony stimulating factor(G-CSF), h...

    Authors: Kyung Taek Hong, Hyoung Jin Kang, Nam Hee Kim, Min Sun Kim, Ji Won Lee, Hyery Kim, Kyung Duk Park, Hee Young Shin and Hyo Seop Ahn
    Citation: Journal of Hematology & Oncology 2012 5:14
    Content type: Letter to the Editor Published on:

  14. The ASXL1 gene is one of the most frequently mutated genes in malignant myeloid diseases. The ASXL1 protein belongs to protein complexes involved in the epigenetic regulation of gene expression. ASXL1 mutations a...

    Authors: Véronique Gelsi-Boyer, Mandy Brecqueville, Raynier Devillier, Anne Murati, Marie-Joelle Mozziconacci and Daniel Birnbaum
    Citation: Journal of Hematology & Oncology 2012 5:12
    Content type: Review Published on:

  17. MicroRNAs (miRNAs) are short non-coding RNAs that are involved in several important biological processes through regulation of genes post-transcriptionally. Carcinogenesis is one of the key biological processe...

    Authors: Oudai Hassan, Aamir Ahmad, Seema Sethi and Fazlul H Sarkar
    Citation: Journal of Hematology & Oncology 2012 5:9
    Content type: Review Published on:

  19. MicroRNAs are small RNA molecules that regulate gene expression and play critical roles in B cell development and malignancy. miRNA expression is important globally, as B cell specific knockouts of Dicer show ...

    Authors: Thilini R Fernando, Norma I Rodriguez-Malave and Dinesh S Rao
    Citation: Journal of Hematology & Oncology 2012 5:7
    Content type: Review Published on:

  20. Aplastic anemia (AA) is characterized by pancytopenia and bone marrow hypoplasia, which results from immune-mediated hematopoiesis suppression. Understanding the pathophysiology of the immune system, particula...

    Authors: Bo Li, Sichu Liu, Yuzhe Niu, Su Fang, Xiuli Wu, Zhi Yu, Shaohua Chen, Lijian Yang and Yangqiu Li
    Citation: Journal of Hematology & Oncology 2012 5:6
    Content type: Rapid communication Published on:

  21. Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes encode cytosolic and mitochondrial enzymes that catalyze the conversion of isocitrate to α-ketoglutarate. Acquired somatic mutations of IDH1 and ID...

    Authors: Sadudee Chotirat, Wanna Thongnoppakhun, Orathai Promsuwicha, Chetsada Boonthimat and Chirayu U Auewarakul
    Citation: Journal of Hematology & Oncology 2012 5:5
    Content type: Research Published on:

  22. While lenalidomide (LEN) shows high efficacy in myelodysplastic syndromes (MDS) with del[5q], responses can be also seen in patients presenting without del[5q]. We hypothesized that improved detection of chrom...

    Authors: Yuka Sugimoto, Mikkael A Sekeres, Hideki Makishima, Fabiola Traina, Valeria Visconte, Anna Jankowska, Andres Jerez, Hadrian Szpurka, Christine L O'Keefe, Kathryn Guinta, Manuel Afable, Ramon Tiu, Kathy L McGraw, Alan F List and Jaroslaw Maciejewski
    Citation: Journal of Hematology & Oncology 2012 5:4
    Content type: Research Published on:

  23. Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alp...

    Authors: Byung Lee, Nikhil Mukhi and Delong Liu
    Citation: Journal of Hematology & Oncology 2012 5:3
    Content type: Review Published on:

  24. Essential Thrombocythemia (ET) and Primary Myelofibrosis (PMF) are Chronic Myeloproliferative Neoplasms (MPN) characterized by clonal myeloproliferation/myeloaccumulation without cell maturation impairment. Th...

    Authors: Raquel Tognon, Elainy PL Gasparotto, Renata P Neves, Natália S Nunes, Aline F Ferreira, Patrícia VB Palma, Simone Kashima, Dimas T Covas, Mary Santana, Elizabeth X Souto, Maria Aparecida Zanichelli, Belinda P Simões, Ana Maria de Souza and Fabíola A Castro
    Citation: Journal of Hematology & Oncology 2012 5:2
    Content type: Research Published on:

  25. Speciation of arsenic trioxide (ATO) metabolites in clinical samples such as peripheral blood (PB) from acute promyelocytic leukemia (APL) patients has been conducted. However, speciation of arsenicals in bone...

    Authors: Noriyoshi Iriyama, Yuta Yoshino, Bo Yuan, Akira Horikoshi, Yukio Hirabayashi, Yoshihiro Hatta, Hiroo Toyoda and Jin Takeuchi
    Citation: Journal of Hematology & Oncology 2012 5:1
    Content type: Research Published on:

  26. Infantile hemangiomas (IH) are the most common benign tumors of infancy. The typical clinical course consists of rapid growth during the first year of life, followed by natural and gradual involution over a mu...

    Authors: Dan Xu, Teresa M O, Archil Shartava, Taylor C Fowles, Jianchang Yang, Louis M Fink, David C Ward, Martin C Mihm, Milton Waner and Yupo Ma
    Citation: Journal of Hematology & Oncology 2011 4:54
    Content type: Research Published on:

  27. Dabigatran is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. It has been approved in the European Union and the United States of America for the prevention of thrombosis after...

    Authors: Santiago Redondo, Maria-Paz Martínez, Marta Ramajo, Jorge Navarro-Dorado, Abelardo Barez and Teresa Tejerina
    Citation: Journal of Hematology & Oncology 2011 4:53
    Content type: Review Published on:

  28. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in various tumor cells, but does not affect normal cells or human leukemic cells, such as MOLT-4 and U937 cells, which are rela...

    Authors: Benjawan Wudtiwai, Bungorn Sripanidkulchai, Prachya Kongtawelert and Ratana Banjerdpongchai
    Citation: Journal of Hematology & Oncology 2011 4:52
    Content type: Research Published on:

  29. Although the majority of published cases of lead poisoning come from occupational exposures, some traditional remedies may also contain toxic amounts of lead. Ayurveda is a system of traditional medicine that ...

    Authors: Krishna S Gunturu, Priyadharsini Nagarajan, Peter McPhedran, Thomas R Goodman, Michael E Hodsdon and Matthew P Strout
    Citation: Journal of Hematology & Oncology 2011 4:51
    Content type: Case report Published on:

  30. Regulatory T cells (Tregs) are a specialized subpopulation of CD4+ T cells, which act to suppress the activation of other immune cells. Tregs represent important modulators for the interaction between lymphomas a...

    Authors: Jing Wang and Xiao-Yan Ke
    Citation: Journal of Hematology & Oncology 2011 4:50
    Content type: Review Published on:

  31. Most non-Hodgkin's lymphomas (NHL) initially respond to chemotherapy, but relapse is common and treatment is often limited by chemotherapy-related toxicity. Bortezomib, is a highly selective proteasome inhibit...

    Authors: Shiloh M Martin, Eric Churchill, Hayes McKnight, Christopher M Mahaffey, Yunpeng Ma, Robert T O'Donnell and Joseph M Tuscano
    Citation: Journal of Hematology & Oncology 2011 4:49
    Content type: Research Published on:

  32. Regulatory T cells (Treg) that express the transcription factor Foxp3 are enriched within a broad range of murine and human solid tumors. The ontogeny of these Foxp3 Tregs - selective accumulation or prolifera...

    Authors: Jon G Quatromoni, Lilah F Morris, Timothy R Donahue, Yue Wang, William McBride, Talal Chatila and James S Economou
    Citation: Journal of Hematology & Oncology 2011 4:48
    Content type: Research Published on:

  33. Light chain (AL) amyloidosis is a plasma cell dyscrasia characterized by the pathologic production of fibrillar proteins comprised of monoclonal light chains which deposit in tissues and cause organ dysfunctio...

    Authors: Michael Rosenzweig and Heather Landau
    Citation: Journal of Hematology & Oncology 2011 4:47
    Content type: Review Published on:

  34. The regimen of cytarabine, aclarubicin and G-CSF (CAG) has been widely used in China and Japan for treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). We searched literature on CAG be...

    Authors: Guoqing Wei, Wanmao Ni, Jen-wei Chiao, Zhen Cai, He Huang and Delong Liu
    Citation: Journal of Hematology & Oncology 2011 4:46
    Content type: Research Published on:

  35. Acute megakaryoblastic leukemia (AMKL) is a type of acute myeloid leukemia (AML), in which majority of the blasts are megakaryoblastic. De novo AMKL in adulthood is rare, and carries very poor prognosis. We he...

    Authors: Xiao Min, Zhang Na, Liu Yanan and Li Chunrui
    Citation: Journal of Hematology & Oncology 2011 4:45
    Content type: Case report Published on:

  36. Anti-platelet therapy plays an important role in the treatment of patients with thrombotic diseases. The most commonly used anti-platelet drugs, namely, aspirin, ticlopidine, and clopidogrel, are effective in ...

    Authors: Xuebin Ji and Ming Hou
    Citation: Journal of Hematology & Oncology 2011 4:44
    Content type: Review Published on:

  37. Idiopathic chronic neutropenia (ICN) describes a heterogeneous group of hematologic diseases characterized by low circulating neutrophil levels often associated with recurrent fevers, chronic mucosal inflammat...

    Authors: Roger M Lyons, Sharon T Wilks, Shelby Young and Gail L Brown
    Citation: Journal of Hematology & Oncology 2011 4:43
    Content type: Case report Published on:

  38. The MRC UKALLXI trial tested the efficacy of different central nervous system (CNS) directed therapies in childhood acute lymphoblastic leukaemia (ALL). To evaluate morbidity 555/1826 randomised children under...

    Authors: Christina Halsey, Georgina Buck, Sue Richards, Faraneh Vargha-Khadem, Frank Hill and Brenda Gibson
    Citation: Journal of Hematology & Oncology 2011 4:42
    Content type: Research Published on:

  40. Ph- myeloproliferative neoplasms (MPNs) represent a heterogeneous group of chronic diseases characterized by increased expansion of hematopoietic cells of the myeloid lineage. JAK2V617F, an activation mutation...

    Authors: Anna H Zhao, Rufei Gao and Zhizhuang J Zhao
    Citation: Journal of Hematology & Oncology 2011 4:40
    Content type: Short report Published on:

  41. A 54-year-old woman was diagnosed with infiltrative ductal breast carcinoma. Two years after treatment, the patient developed an acute myeloid leukemia (AML) which harbored del(11q23) in 8% of the blast cells....

    Authors: Hilda Rachel Diamond, Maria Helena Ornellas, Alberto Orfao, Bernadete E Gomes, Mércia M Campos, Teresa S Fernandez, Roberto I da Silva, Gilda Alves, Claudia Lage, Dayse A da Silva, Arthur Moellmann-Coelho, Geydson S da Cruz, Luis Fernando Bouzas and Eliana Abdelhay
    Citation: Journal of Hematology & Oncology 2011 4:39
    Content type: Case report Published on:

  42. Sall4 is a key factor for the maintenance of pluripotency and self-renewal of embryonic stem cells (ESCs). Our previous studies have shown that Sall4 is a robust stimulator for human hematopoietic stem and pro...

    Authors: Jianchang Yang, Jerell R Aguila, Zaida Alipio, Raymond Lai, Louis M Fink and Yupo Ma
    Citation: Journal of Hematology & Oncology 2011 4:38
    Content type: Research Published on:

  43. The bone marrow microenvironment facilitates the survival, differentiation, and proliferation of myeloma (MM) cells. This study identified that microRNA-15a and -16 expressions tightly correlated with prolifer...

    Authors: Mu Hao, Li Zhang, Gang An, Weiwei Sui, Zhen Yu, Dehui Zou, Yan Xu, Hong Chang and Lugui Qiu
    Citation: Journal of Hematology & Oncology 2011 4:37
    Content type: Letter to the Editor Published on:

  45. Bladder cancer occurs in the majority of cases in males. It represents the seventh most common cancer and the ninth most common cause of cancer deaths for men. Transitional cell carcinoma is the most predomina...

    Authors: Nabil Ismaili, Mounia Amzerin and Aude Flechon
    Citation: Journal of Hematology & Oncology 2011 4:35
    Content type: Review Published on:

  46. Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes. The aim of this study was to evaluate whether lymphopenia at...

    Authors: Yu Ri Kim, Jin Seok Kim, Soo Jeong Kim, Hyun Ae Jung, Seok Jin Kim, Won Seog Kim, Hye Won Lee, Hyeon Seok Eom, Seong Hyun Jeong, Joon Seong Park, June-Won Cheong and Yoo Hong Min
    Citation: Journal of Hematology & Oncology 2011 4:34
    Content type: Research Published on:

  47. The role of thymidylate synthase (TS) is essential as a key rate-limiting enzyme in DNA synthesis. It is the primary target of fluorouracil and its derivates in colorectal cancer. In this study, TS mRNA expres...

    Authors: Yanyan Liu, Qingxin Xia, Yanzhao Jia, Hongqiang Guo, Bing Wei, Yawei Hua and Shujun Yang
    Citation: Journal of Hematology & Oncology 2011 4:33
    Content type: Letter to the Editor Published on:

  48. Nilotinib is approved for treatment of newly diagnosed chronic myeloid leukemia (CML) and it is shown superiority over imatinib in first-line treatment for patients of CML. In this study, we established a nilo...

    Authors: Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka and Kazuma Ohyashiki
    Citation: Journal of Hematology & Oncology 2011 4:32
    Content type: Letter to the Editor Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 29.9
    5-year Journal Impact Factor: 27.1
    Source Normalized Impact per Paper (SNIP): 4.489
    SCImago Journal Rank (SJR): 7.522

    Speed 2024
    Submission to first editorial decision (median days): 4
    Submission to acceptance (median days): 61

    Usage 2024
    Downloads: 3,430,659
    Altmetric mentions: 1,308

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us